(Q2744099)

French Wikipedia

logo image

VertexPharma-logo2.png
271 × 166; 6 KB

1 reference

chief executive officer

Jeffrey Leiden

February 2012

end time

March 2020

0 references

Reshma Kewalramani

April 2020

0 references

country

United States of America

1 reference

grid.422219.e

total revenue

175,504,000 United States dollar

2008

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746911001025/a2201820z10-k.htm

17 February 2011

101,889,000 United States dollar

2009

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746911001025/a2201820z10-k.htm

17 February 2011

143,370,000 United States dollar

2010

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746911001025/a2201820z10-k.htm

17 February 2011

1,410,626,000 United States dollar

2011

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746912001298/a2206536z10-k.htm

22 February 2012

1,527,042,000 United States dollar

2012

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532013000009/vrtx10k_12312012.htm

1 March 2013

1,211,975,000 United States dollar

2013

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532014000015/a201310k.htm

11 February 2014

580,415,000 United States dollar

2014

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532015000012/a201410k-main.htm

13 February 2015

1,032,336,000 United States dollar

2015

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532016000067/a201510k-main.htm

16 February 2016

1,702,177,000 United States dollar

2016

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532017000017/a201610k-main.htm

23 February 2017

2,488,652,000 United States dollar

2017

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532018000009/a201710k-main.htm

15 February 2018

3,047,597,000 United States dollar

2018

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532019000006/a201810k-main.htm

13 February 2019

4,162,821,000 United States dollar

2019

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532020000007/a201910k-main.htm

13 February 2020

6,205,683,000 United States dollar

2020

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532021000006/vrtx-20201231.htm

11 February 2021

7,574,400,000 United States dollar

2021

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532022000007/vrtx-20211231.htm

9 February 2022

8,930,700,000 United States dollar

2022

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532023000007/vrtx-20221231.htm

10 February 2023

−642,178,000 United States dollar

2009

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746912001298/a2206536z10-k.htm

22 February 2012

−754,626,000 United States dollar

2010

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746912001298/a2206536z10-k.htm

22 February 2012

29,574,000 United States dollar

2011

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746912001298/a2206536z10-k.htm

22 February 2012

−107,032,000 United States dollar

2012

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532013000009/vrtx10k_12312012.htm

1 March 2013

−445,028,000 United States dollar

2013

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532014000015/a201310k.htm

11 February 2014

−738,555,000 United States dollar

2014

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532015000012/a201410k-main.htm

13 February 2015

−556,334,000 United States dollar

2015

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532016000067/a201510k-main.htm

16 February 2016

−112,052,000 United States dollar

2016

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532017000017/a201610k-main.htm

23 February 2017

263,484,000 United States dollar

2017

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532018000009/a201710k-main.htm

15 February 2018

2,096,896,000 United States dollar

2018

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532019000006/a201810k-main.htm

13 February 2019

1,176,810,000 United States dollar

2019

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532020000007/a201910k-main.htm

13 February 2020

2,711,647,000 United States dollar

2020

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532021000006/vrtx-20201231.htm

11 February 2021

2,342,100,000 United States dollar

2021

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532022000007/vrtx-20211231.htm

9 February 2022

3,322,000,000 United States dollar

2022

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532023000007/vrtx-20221231.htm

10 February 2023

−462,708,000 United States dollar

2008

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746911001025/a2201820z10-k.htm

17 February 2011

−614,012,000 United States dollar

2009

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746911001025/a2201820z10-k.htm

17 February 2011

−696,077,000 United States dollar

2010

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746911001025/a2201820z10-k.htm

17 February 2011

113,820,000 United States dollar

2011

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000104746912001298/a2206536z10-k.htm

22 February 2012

2,332,000 United States dollar

2012

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532013000009/vrtx10k_12312012.htm

1 March 2013

−903,448,000 United States dollar

2013

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532014000015/a201310k.htm

11 February 2014

−692,412,000 United States dollar

2014

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532015000012/a201410k-main.htm

13 February 2015

−466,879,000 United States dollar

2015

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532016000067/a201510k-main.htm

16 February 2016

9,936,000 United States dollar

2016

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532017000017/a201610k-main.htm

23 February 2017

123,243,000 United States dollar

2017

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532018000009/a201710k-main.htm

15 February 2018

635,150,000 United States dollar

2018

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532019000006/a201810k-main.htm

13 February 2019

1,197,566,000 United States dollar

2019

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532020000007/a201910k-main.htm

13 February 2020

2,856,290,000 United States dollar

2020

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532021000006/vrtx-20201231.htm

11 February 2021

2,782,100,000 United States dollar

2021

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532022000007/vrtx-20211231.htm

9 February 2022

4,307,400,000 United States dollar

2022

1 reference

https://www.sec.gov/Archives/edgar/data/0000875320/000087532023000007/vrtx-20221231.htm

10 February 2023

Vertex Pharmaceuticals (United Kingdom)

1 reference

grid.476839.7

headquarters location

Boston

1 reference

VRTX

1 reference

product or material produced or service provided

medication

1 reference

https://en.wikipedia.org/w/index.php?title=Vertex_Pharmaceuticals&oldid=992004314

Wikimedia import URL

official website

http://www.vrtx.com/

1 reference

https://www.forbes.com/companies/vertex-pharmaceuticals/

described at URL

0 references

https://www.forbes.com/sites/matthewherper/2017/08/08/vertex-pharmaceuticals-and-the-price-of-inspiration/

0 references

https://www.bostonglobe.com/magazine/2017/12/13/vertex/zO9My0GXMQ4rjYz28CbIhI/story.html

0 references

https://www.bostonglobe.com/business/2017/10/16/vertex-pledges-for-charitable-efforts-over-next-years/farofoHx1RzLHtqbbk9jUP/story.html

0 references

https://www.cnbc.com/2018/01/31/vertex-chooses-two-drugs-to-advance-in-cystic-fibrosis-triple-combinations.html

0 references

https://www.bostonglobe.com/opinion/2018/06/03/facing-stem-challenge-education/19E2V4EUpSzoh118SEQt3O/story.html

0 references

https://www.sdbj.com/news/2018/jun/19/vertex-pharmaceuticals-expands-san-diego-footprint/

0 references

https://www.forbes.com/sites/matthewherper/2017/07/18/new-vertex-drugs-show-dramatic-benefit-in-cystic-fibrosis/#6bb266392f95

https://www3.bostonglobe.com/business/2017/06/05/vertex-goes-all-its-effort-conquer-cystic-fibrosis/sIUBpbtItPoiyKDsyGcxRP/story.html?arc404=true

0 references

https://www.investors.com/research/the-new-america/vertex-plans-to-eradicate-cystic-fibrosis-and-go-from-there

0 references

https://cysticfibrosisnewstoday.com/2018/09/04/vertex-cystic-fibrosis-and-steps-on-long-road-to-medical-history-part-one-interview-series

0 references

https://beststocks.com/institutional-investors-show-interest-in-biotech-c/

0 references

https://www.businesswire.com/news/home/20230623446641/en/Vertex-Presents-Positive-VX-880-Results-From-Ongoing-Phase-12-Study-in-Type-1-Diabetes-at-the-American-Diabetes-Association-83rd-Scientific-Sessions

0 references

https://www.fiercepharma.com/pharma/after-early-win-type-1-diabetes-vertex-joins-forces-lonza-new-cell-therapy-production-plant

0 references

https://www.evaluate.com/vantage/articles/events/conferences/ada-2023-vertex-raises-hopes-type-1-diabetes-cure

0 references

https://www.biospace.com/article/vertex-trial-data-shows-two-t1d-patients-reach-insulin-independence-with-cell-therapy

0 references

https://www.statnews.com/2023/06/23/vertex-diabetes-cell-therapy-insulin/

0 references

https://finance.yahoo.com/news/vertex-lonza-build-dedicated-manufacturing-113000348.html

0 references

https://www.claytoncountyregister.com/uncategorized/exploring-the-innovative-drug-discoveries-of-vertex-pharmaceuticals-incorporated/25866/

0 references

0 references

social media followers

65,516

4 January 2021

0 references

64,089

24 April 2020

0 references

67,938

9 January 2022

0 references

70,191

10.6084/M9.FIGSHARE.4539889

6 February 2023

0 references

Commons category

Vertex Pharmaceuticals

0 references

Identifiers

0 references

1 reference

National Library of Israel J9U ID

987007603695005171

1 reference

National Library of Israel Names and Subjects Authority File

Library of Congress authority ID

0 references

1 reference

https://en.wikipedia.org/w/index.php?title=List_of_S%26P_500_companies&oldid=986445016

Comparably company ID

vertex-pharmaceuticals

1 reference

https://www.comparably.com/companies/vertex-pharmaceuticals

title

Vertex Pharmaceuticals Company Culture | Comparably (English)

retrieved

26 June 2022

Crunchbase organization ID

vertex-pharmaceuticals

1 reference

http://km.aifb.kit.edu/services/crunchbase/

0 references

1 reference

28 October 2013

Vertex_Pharmaceuticals-W3XAYA

0 references

grid.422219.e

2 references

GRID Release 2016-05-31

LinkedIn company or organization ID

GRID Release 2016-12-06

vertex-pharmaceuticals

0 references

Microsoft Academic ID

61970326

1 reference

Microsoft Academic Knowledge Graph

Open Funder Registry funder ID

grid.422219.e

retrieved

19 January 2019

1 reference

7 December 2017

1 reference

https://docs.openalex.org/download-snapshot/snapshot-data-format

25 January 2022

0 references

Vertex-Pharmaceuticals

1 reference

1 reference

Aligned ISNI and Ringgold identifiers for institutions

0 references

verified account or profile

number of subscribers

64,089

21 November 2008

UK Parliament thesaurus ID

24 April 2020

0 references

VertexPharma

0 references

85611

subject named as

Vertex

0 references

YouTube channel ID

UCrNu_QIE9exwVQnWKgr1toQ

subject named as

Vertex Pharmaceuticals

number of viewers/listeners

27 July 2018

number of works

106

275,768